Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results, Misses Expectations By $0.19 EPS

Xeris Biopharma (NASDAQ:XERS) released its earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19), FiscalAI reports. The firm had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Second-quarter revenue reached a record $92.1 million, with net product revenue up 34% year over year to $91 million; adjusted EBITDA increased more than 50% to $19.3 million.
• RECORLEV revenue surged 81% to $56.8 million, supported by record referrals, new patient starts, and prescriber growth. Management expects the expanded commercial team to contribute further in the second half.
• Xeris raised and narrowed full-year 2026 revenue guidance to $385 million-$390 million, citing sustained portfolio momentum and an expected rebound in Gvoke, while KEVEYIS received a patent allowance that could extend protection through at least 2039.
• The company fully retired its $34 million of convertible debt in July, eliminating approximately $3 million in annual interest expense and simplifying the balance sheet, although the transaction generated a one-time, non-cash GAAP charge of about $31 million in the second quarter.
• Xeris plans to increase full-year SG&A by approximately $50 million and R&D by $25 million versus 2025, primarily to support RECORLEV expansion and the planned year-end Phase III start for XP-8121; management expects R&D spending to rise further as the trial ramps in 2027.

Xeris Biopharma Price Performance

XERS traded down $0.75 during midday trading on Thursday, reaching $7.36. 3,723,333 shares of the company’s stock were exchanged, compared to its average volume of 1,503,106. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The business has a 50-day simple moving average of $7.64 and a two-hundred day simple moving average of $6.79. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of 122.67 and a beta of 0.66. Xeris Biopharma has a one year low of $5.25 and a one year high of $10.08.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Xeris Biopharma presently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Insider Buying and Selling

In other news, insider Beth Hecht sold 16,666 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $8.01, for a total value of $133,494.66. Following the completion of the transaction, the insider directly owned 1,144,462 shares of the company’s stock, valued at approximately $9,167,140.62. This represents a 1.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John Johnson sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $91,350.00. Following the transaction, the director owned 683,083 shares of the company’s stock, valued at $4,159,975.47. This trade represents a 2.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 266,499 shares of company stock worth $1,996,417. Insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

Several large investors have recently made changes to their positions in XERS. Royal Bank of Canada boosted its position in Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after buying an additional 198,984 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Xeris Biopharma by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares during the last quarter. Millennium Management LLC raised its position in Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after purchasing an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP acquired a new position in Xeris Biopharma in the first quarter worth $170,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.